• Explore /
  • Poster
  • / Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.

Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.

Abstract Video & Slides Poster

Authors

Damon Reed

Damon R. Reed

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Damon R. Reed , Sant P. Chawla , Bhuvana Setty , Leo Mascarenhas , Paul A. Meyers , Jonathan Metts , Douglas James Harrison , Stephen L. Lessnick , Brian D. Crompton , David Loeb , David D. Stenehjem , David S. Wages , Daniela Y. Santiesteban , Nadeem Q. Mirza , Steven G. DuBois

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT03600649

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS11577)

DOI

10.1200/JCO.2021.39.15_suppl.TPS11577

Abstract #

TPS11577

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Gregory Michael Cote

First Author: Damon R. Reed

First Author: Samer Ali Srour

First Author: Kelly C. Goldsmith